Teva Signs an Exclusive Commercialization Agreement with Bioeq for FYB201 ( biosimilar- ranibizumab)
Teva teams up on biosims with Celltrion three years after its Lonza JV divorce | Fierce Biotech
Teva teams with Celltrion in $160m biosimilar deal - Globes
FDA Approves Celltrion's Truxima, a Biosimilar to Rituxan, for Treatment of Adult Patients with Non-Hodgkin's Lymphoma | Specialty Pharma Journal
Celltrion and Teva announce first Rituxan biosimilar approval in US
FDA panel unanimously backs Celltrion's Rituxan biosimilar | Fierce Pharma
Pfizer's rituximab biosimilar gets late-stage trial boost
Teva and Celltrion Launch Rituximab Biosimilar in US - Big Molecule Watch
Teva's (TEVA) Filing for Biosimilar Rituxan Accepted by FDA
Teva and Celltrion Launch Truxima (biosimilar- rituximab) to Treat Wegener's Granulomatosis and Microscopic Polyangiitis in the US
Riabni™ (rituximab-arrx) – New biosimilar approval
Home - TRUXIMA® (rituximab-abbs) HCP site.
Top 25 Biosimilar Drug Manufacturers 2019 - Visiongain Research Report
Say hello to Roche's worst-case scenario: Teva's Rituxan biosim set to launch in U.S. | Fierce Pharma
Teva Pharmaceuticals 63459010450 - McKesson Medical-Surgical
Teva launches rituximab biosimilar Truxima in US
Roche faces prospect of second Rituxan biosimilar in US - PMLiVE
Roche's patent cliff just got steeper as FDA approves Celltrion's Rituxan biosimilar Truxima | Fierce Pharma
Global Rituximab Biosimilar Market Assessment –Clinical Trial/Pipeline Analysis, Brand/Originator Drug Historic Revenue and Forecast 2019- 2027 | Medgadget
Teva and Celltrion Announce the Availability of TRUXIMA® (rituximab-abbs) Injection, the First Biosimilar to Rituxan® (rituximab) in the United States | Business Wire
Celltrion's Truxima (rituximab-abbs) Biosimilar Product Profile
Teva, Celltrion get FDA nod for biosimilar to Roche's cancer drug Rituxan
About Biosimilars - TRUXIMA® (rituximab-abbs)
Teva's Rituxan Biosimilar Gets FDA Nod in Non-Hodgkin Lymphoma
Teva/Celltrion's Truxima Is First Biosimilar Rituxan To Reach US Market :: Scrip
Teva: Biosimilars In The US Will Become Like Complex Generics :: Generics Bulletin
